H
Hiroaki Yagyu
Researcher at University of Tsukuba
Publications - 26
Citations - 893
Hiroaki Yagyu is an academic researcher from University of Tsukuba. The author has contributed to research in topics: Diabetes mellitus & Type 2 Diabetes Mellitus. The author has an hindex of 10, co-authored 23 publications receiving 794 citations. Previous affiliations of Hiroaki Yagyu include Wake Forest University & Jichi Medical University.
Papers
More filters
Journal ArticleDOI
Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity
Jun-ichi Osuga,Shun Ishibashi,Teruaki Oka,Hiroaki Yagyu,Ryu-ichi Tozawa,Akihisa Fujimoto,Futoshi Shionoiri,Naoya Yahagi,Frederic B. Kraemer,Osamu Tsutsumi,Nobuhiro Yamada +10 more
TL;DR: It is shown that HSL is required for spermatogenesis but is not the only enzyme that mediates the hydrolysis of triacylglycerol stored in adipocytes, and that adipocytes were significantly enlarged and the size differences between cell and tissue suggests the heterogeneity of adipocytes.
Journal ArticleDOI
Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins – ODYSSEY JAPAN Randomized Controlled Trial –
Tamio Teramoto,Masahiko Kobayashi,Hiromi Tasaki,Hiroaki Yagyu,Toshinori Higashikata,Yoshiharu Takagi,Kiyoko Uno,Marie T. Baccara-Dinet,Atsushi Nohara +8 more
TL;DR: In high-risk Japanese patients with hypercholesterolemia on stable statin therapy, alirocumab markedly reduced LDL-C vs. placebo and was well tolerated over 52 weeks.
Journal ArticleDOI
Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus.
TL;DR: The aim of the present study was to investigate the effects of 24 weeks of treatment with liraglutide on cardiovascular risk markers such as BNP, d-ROMs, and MDA in patients with T2DM.
Journal ArticleDOI
Myeloid HMG-CoA (3-Hydroxy-3-Methylglutaryl-Coenzyme A) Reductase Determines Atherosclerosis by Modulating Migration of Macrophages
Kent Sakai,Shuichi Nagashima,Tetsuji Wakabayashi,Bayasgalan Tumenbayar,Hiroko Hayakawa,Morisada Hayakawa,Tadayoshi Karasawa,Ken Ohashi,Hisataka Yamazaki,Akihito Takei,Shoko Takei,Daisuke Yamamuro,Manabu Takahashi,Hiroaki Yagyu,Jun-ichi Osuga,Masafumi Takahashi,Shin-ichi Tominaga,Shun Ishibashi +17 more
TL;DR: Genetic reduction of HMGCR in myeloid cells may exert atheroprotective effects primarily by decreasing the migratory activity of monocytes/macrophages to the lesions.
Journal ArticleDOI
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry.
Yoshikazu Sawada,Yoshihiko Izumida,Yoshinori Takeuchi,Yuichi Aita,Nobuhiro Wada,EnXu Li,Yuki Murayama,Xianying Piao,Akito Shikama,Yukari Masuda,Makiko Nishi-Tatsumi,Midori Kubota,Motohiro Sekiya,Takashi Matsuzaka,Yoshimi Nakagawa,Yoko Sugano,Hitoshi Iwasaki,Kazuto Kobayashi,Shigeru Yatoh,Hiroaki Suzuki,Hiroaki Yagyu,Yasushi Kawakami,Takashi Kadowaki,Hitoshi Shimano,Naoya Yahagi,Naoya Yahagi +25 more
TL;DR: The results indicated that SGLT2 inhibition triggered glycogen depletion signal and actuated liver-brain-adipose axis, resulting in PKA activation in adipocytes, and it was concluded that the effect of SGLt2 inhibition on weight loss is in part mediated via the liver- Brain-Adipose neurocircuitry.